Develop an inpatient venous thromboembolism prevention protocol: risk stratification,…
- User
Develop an inpatient venous thromboembolism prevention protocol: risk stratification, pharmacologic vs mechanical prophylaxis, contraindication management, monitoring, and discharge instructions.
- Assistant
Inpatient Venous Thromboembolism (VTE) Prevention Protocol
Purpose: To standardize VTE prophylaxis for hospitalized adult patients (medical and surgical) to reduce risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), per ACCP/CHEST 2021 guidelines, ASH 2020, and hospital quality metrics.
Scope: All non-ICU inpatients ≥18 years. ICU patients follow separate protocol. Obstetrics/pediatrics excluded.
Implementation:
- VTE Risk Assessment (RA) completed within 24 hours of admission and q72h or change in status (e.g., surgery, immobility).
- Nursing/physician co-responsible. Document in EHR VTE flow sheet.
- Multidisciplinary VTE committee reviews compliance quarterly.
1. Risk Stratification
Assess VTE risk (using Padua score for medical; Caprini for surgical) AND Bleeding risk (IMPROVE Bleed score). Scores available in EHR calculator.
VTE Risk Categories
Risk Level Padua Score (Medical) Caprini Score (Surgical) Examples Low 0–3 0–1 Minor surgery, fully mobile Moderate 4–High (≥4) 2–4 Acute MI, CHF, cancer, age ≥70, immobility High ≥4 (with prior VTE) or very high ≥5 Prior VTE, thrombophilia, ortho/spine surgery, bariatric Bleeding Risk Categories
Risk Level IMPROVE Bleed Score Examples Low 0–6 No recent bleed, normal platelets/renal function High ≥7 Active bleed, platelets <50k, CrCl <30 mL/min, recent surgery/trauma/stroke, age ≥75 + anemia Overall Prophylaxis Decision: Use matrix below.
2. Prophylaxis Recommendations
Prophylaxis Matrix
VTE Risk / Bleeding Risk Low Bleed High Bleed Low VTE None None Moderate VTE Pharmacologic (preferred) OR Mechanical Mechanical (preferred) OR None if absolute contraindication High VTE Pharmacologic (± Mechanical) Mechanical (± reassess pharma after 48h) - Preferred: Pharmacologic for moderate-high VTE/low bleed.
- Mechanical alone: High bleed OR pharma contraindication.
- No prophylaxis: Low VTE risk AND low bleed (reassess q72h).
Pharmacologic Prophylaxis
Agent Standard Dose Adjustments Notes Enoxaparin (LMWH) 40 mg SQ q24h 30 mg q24h if wt ≤50 kg or CrCl <30 Preferred; renal-adjusted Heparin (UFH) 5,000 units SQ q8h 5,000 units SQ q12h if high bleed/renal Alternative if LMWH unavailable Fondaparinux 2.5 mg SQ q24h Avoid if CrCl <30 Use in HIT-suspect - Start within 24h of admission (12h post-op if low bleed).
- Surgical: Omit 12–24h pre-op; resume 6–12h post-op.
Mechanical Prophylaxis
- Intermittent Pneumatic Compression Devices (IPCD): Preferred (arms/legs). Use 24h/day except ADLs/hygiene.
- Graduated Compression Stockings (GCS): If IPCD contraindicated/unavailable (knee-high, 15–30 mmHg).
- Combine with pharmacologic when possible.
3. Contraindication Management
Absolute Contraindications to Pharmacologic
- Active bleed, ICH within 3 mo, epidural within 12h, platelets <20k, neurosurgery within 72h.
- Management: Mechanical only. Reassess q24–48h.
Relative Contraindications to Pharmacologic (High Bleed Risk)
- Platelets 20–50k, recent GI/GU bleed, liver failure.
- Management: Hold pharma; use mechanical. Restart when resolved (e.g., platelets >50k).
Contraindications to Mechanical
IPCD GCS - Severe PVD/ischemia- Fresh amputation- Skin breakdown- Paralysis/contractures- CHF (leg edema) - Same as IPCD- Arterial insufficiency (ABI <0.6) Management: No mechanical → early ambulation, pharmacologic if low bleed, or consult Hematology.
Special Populations
- Obese (BMI >40): Enoxaparin 0.5 mg/kg q24h.
- CrCl 15–30: UFH preferred.
- Cancer: LMWH preferred; consider DOAC outpatient.
- Hip/Knee Arthroplasty: Continue 10–35 days post-discharge.
- HIT History/Suspect: Avoid heparin; use fondaparinux or argatroban (therapeutic dose).
4. Monitoring
-
Daily Nursing Assessment (EHR documentation):
- VTE signs: Leg swelling/pain, dyspnea, chest pain.
- Bleeding: Hb/Plt q24–48h initially, then q72h; inspect sites.
- Mechanical: Skin integrity, fit, compliance (>80%).
- HIT: Monitor Plt q2–3 days (4T score if drop >50%).
-
Physician Review: q72h or change (e.g., D-dimer if high suspicion; US/duplex if symptomatic).
-
Labs: CBC, Cr, PT/PTT baseline; aPTT not needed for prophylaxis.
-
Adverse Events:
Event Action Bleeding Hold agent; transfuse prn; reverse with protamine (UFH/LMWH partial) HIT Stop heparin; start argatroban; confirm with serotonin assay Skin Injury Discontinue mechanical; wound care -
Audit: 95% compliance target; report failures to VTE committee.
5. Duration
- Medical: Hospitalization or until fully mobile.
- Surgical: 7–10 days (extend to 35 days for ortho, oncology, bariatric).
- Reassess: q72h or discharge; wean if low risk.
6. Discharge Instructions
- Patient Education (verbal + handout/EHR):
- Signs of VTE: Sudden leg pain/swelling, shortness of breath, chest pain, coughing blood → ER immediately.
- Bleeding Signs: Unusual bruising, blood in stool/urine, severe headache → call MD/stop meds.
- Medications: List agents/duration (e.g., enoxaparin 35 days post-hip replacement).
- Lifestyle: Ambulate early, hydrate, avoid crossing legs, smoking cessation.
- Follow-up: Clinic in 7–14 days; extended prophylaxis if high risk (e.g., cancer).
- Prescriptions: Auto-generated for extended rx; LMWH self-injection teaching if outpatient.
- High-Risk Referral: Hematology if prior VTE/thrombophilia.
Approval: VTE Committee [Date].
Revision: Annual or per new guidelines.
Contact: Pharmacy (dosing), Hematology (complex cases).